Navigation Links
Medical molecules designed to respond to visible light that can penetrate tissue

If you have ever covered a flashlight with your hand and seen the red light that still comes through, then you have seen light in the therapeutic window ?that magic wavelength that is not absorbed or reflected away by tissue. Scientists believe that they can use light at that wavelength to signal manmade molecules to release drugs at disease sites in the body.

Such possibilities will be discussed in a poster and a talk by Virginia Tech researchers presenting at the 229th American Chemical Society national meeting in San Diego on March 13-17.

Researchers in Karen Brewer's group at Virginia Tech have designed supramolecular complexes that can hold and, when signaled by light (photoinitiatied), will generate pharmaceutical compounds that can cleave DNA, such as in a tumor cell. "The challenge has been that tissue blocks light so we can't signal molecules deep within the body to deliver drug therapy," says Brewer, associate professor of chemistry.

Matthew Mongelli of Maywood N.J., a postdoctoral associate in chemistry, and his colleagues in chemistry and biology at Virginia Tech, have been working with Theralase Technologies Inc. to design molecular systems that use light that is in the therapeutic window. Starting with a complex with known DNA cleaving qualities, they changed the light absorber unit to one that responds to the red wavelength.

"Investigations into polyazine supermolecular complexes containing Ru and Os with Rh centers that possess photoactive MMCT states: Visible light induced, oxygen independent DNA photocleavage (INOR 329)," will be presented by Mongelli during the general poster session, 7 to 9 p.m., Sunday, March 13, in Convention Center Hall D. The poster has also been selected for the Sci_Mix session 7 to 9 p.m. Monday, March 14, in the Convention Center's Sails Pavilion.

Co-authors are Brewer; undergraduate chemistry students Matthew Jeletic of Centreville, Va. and Jerita Dubash of Ashburn, Va.; and Biology Professor Brenda S. J. Winkel, all of Virginia Tech.

Brewer will also give an oral presentation on designing photochemical molecular devices and applications in photodynamic therapy and in solar energy conversion. Because of the detail offered by Mongelli's poster, Brewer says she will focus on the exciting potential of creating molecules to reduce water to hydrogen. The talk, "Designing photochemical molecular devices utilizing Os and Ru polyazine light absorbers and Rh and Pt reactive sites: Applications in solar energy conversion and photodynamic therapy (INOR 410)," will be presented at 4:50 p.m. Monday, March 14, in Convention Center Room 4. Co-authors are chemistry Ph.D. students Mark Elvington of Blacksburg, Va. and Ran Miao of Zhangzhou City, China, Mongelli, Dubash, Jeletic, and chemistry undergraduate Julie Heinecke of Powhatan, Va.


Source:Virginia Tech

Related biology news :

1. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
2. Medical whistleblowers speak out
3. Medical experts: US unlikely to have enough vaccines to stop avian flu
4. Inflammatory molecules released by pollen trigger allergies
5. DNA constraints control structure of attached macromolecules
6. Scientists discover that three molecules may be developed into new Alzheimers drugs
7. Physical and functional interaction of key cell growth molecules linked to cancer
8. Scientists discover new way to look at how molecules twist and turn on water
9. Scientists learn to predict protein-stabilizing ability of small molecules
10. Tiny RNA molecules fine-tune the brains synapses
11. Convergent evolution of molecules in electric fish
Post Your Comments:

(Date:11/12/2015)... Nov. 11, 2015   Growing need for ... tools has been paving the way for use ... of discrete analytes in clinical, agricultural, environmental, food ... predominantly used in medical applications, however, their adoption ... due to continuous emphasis on improving product quality ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/9/2015)... Nov. 09, 2015 ... of the "Global Law Enforcement Biometrics ... --> ) has announced ... Enforcement Biometrics Market 2015-2019" report to ... Markets ( ) has announced the ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/25/2015)... Nov. 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... in a fireside chat discussion at the Piper Jaffray ... . The discussion is scheduled for Wednesday, December ... .  A replay will be available for 14 ... , Julie NormartVP, Corporate Communications and Business Development ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman ... AngelList early in their initial angel funding process. Now, they are paying it ... to make early stage investments in the microbiome space. In this, they ...
Breaking Biology Technology: